“We don't have any evidence that prescribing testosterone to older men with relatively low testosterone levels does any good,” the National Institute on Aging's Dr. Sergei Romashkan told the AP in September. AndroGel's type of testosterone therapy was approved by the FDA in 2000, but the products still had to contend with a branding challenge: convincing men with low or no testosterone that their condition (known as hypogonadism) wasn't abnormal or anything to be ashamed of. (Más)
But the campaign's empathetic approach and consumer-friendly language resonate with the target audience.
According to IMS Health, in 2011 AndroGel held nearly 49% market share in its category. In 2012, AndroGel passed the $1 billion sales mark in nine months (a 20% jump over the year-ago period), with 3.3 million scripts dispensed, an 18% jump.